Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor
09 April 2024 - 11:00PM
Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology
company focused on developing precision therapies for genetically
defined diseases, today announced new preclinical data from the
Company’s potent, selective, CNS-penetrant ErbB2 inhibitor program.
The data are being presented in a poster session at the American
Association for Cancer Research (AACR) 2024 Annual Meeting taking
place in San Diego, California.
“We’re excited with the progress we’ve made on our ErbB2 program
and look forward to sharing our differentiated profile at this
year’s AACR meeting,” said Andrew Robbins, Cogent’s President and
Chief Executive Officer. “These data further demonstrate Cogent’s
capability to discover and advance potential best-in-class novel
therapies for rare disease populations with high unmet medical
need. Based on these results, we expect to initiate IND-enabling
studies for our potent, selective, CNS-penetrant ErbB2 program in
mid-2024.”
AACR Poster Details
Title: Characterization of a Novel Mutant
Selective, EGFR Sparing, ErbB2 Inhibitor with Activity Across
Activating Mutations in Systemic and CNS TumorsSession
Category: ChemistrySession
Title: Drug Design and in Silico
ScreeningSession Date and Time: Tuesday, Apr
9, 2024 9:00 AM - 12:30 PM PT (12:00 PM – 3:30 PM
ET)Location: Poster Section 20Poster
Board Number: 15Published Abstract
Number: 4486
The poster can be accessed on the ‘Posters and
Publications’ page of Cogent’s website.
Cogent is developing a potential best-in-class EGFR-sparing,
brain-penetrant ErbB2 inhibitor that includes potent coverage of
key mutations (YVMA, S310F, V842I, L755S) inadequately addressed by
currently approved therapies. Activating mutations in the ErbB2
gene have been identified in multiple cancers and demonstrate a
tumorigenic role similar to that of ErbB2 amplification. The poster
presented today describes CGT4255’s exceptional stability in human
whole blood and liver cytosol fractions and high oral
bioavailability and low clearance across preclinical species. In
addition, CGT4255 demonstrated 80% brain penetrance in mice and was
well-tolerated at 10x concentration, resulting in mouse tumor
regression, suggesting potential best-in class properties.
About Cogent Biosciences, Inc.Cogent
Biosciences is a biotechnology company focused on developing
precision therapies for genetically defined diseases. The most
advanced clinical program, bezuclastinib, is a selective tyrosine
kinase inhibitor that is designed to potently inhibit the KIT D816V
mutation as well as other mutations in KIT exon 17. KIT D816V is
responsible for driving systemic mastocytosis, a serious disease
caused by unchecked proliferation of mast cells. Exon 17 mutations
are also found in patients with advanced gastrointestinal stromal
tumors (GIST), a type of cancer with strong dependence on oncogenic
KIT signaling. In addition to bezuclastinib, the Cogent Research
Team is developing a portfolio of novel targeted therapies to help
patients fighting serious, genetically driven diseases initially
targeting mutations in FGFR2, ErbB2 and PI3Ka. Cogent Biosciences
is based in Waltham, MA and Boulder, CO. Visit our website for more
information at www.cogentbio.com. Follow Cogent Biosciences on
social media: X (formerly known as Twitter) and LinkedIn.
Information that may be important to investors will be routinely
posted on our website and X.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, including, but
not limited to, statements regarding the potential best-in-class
properties of the Company’s ErbB2 inhibitor candidate, plans to
initiate IND-enabling studies for the Company’s ErbB2 inhibitor
candidate in mid-2024 and the company’s capability to discover and
advance potential best-in-class novel therapies for rare disease
populations with high unmet medical need. The use of words such as,
but not limited to, "anticipate," "believe," "continue," "could,"
"estimate," "expect," "intend," "may," "might," "plan,"
"potential," "predict," "project," "should," "target," "will," or
"would" and similar words expressions are intended to identify
forward-looking statements. Forward-looking statements are neither
historical facts nor assurances of future performance. Instead,
they are based on our current beliefs, expectations and assumptions
regarding the future of our business, future plans and strategies,
our clinical results, the rate of enrollment in our clinical trials
and other future conditions. New risks and uncertainties may emerge
from time to time, and it is not possible to predict all risks and
uncertainties. No representations or warranties (expressed or
implied) are made about the accuracy of any such forward-looking
statements. We may not actually achieve the forecasts or milestones
disclosed in our forward-looking statements, and you should not
place undue reliance on our forward-looking statements. Such
forward-looking statements are subject to a number of material
risks and uncertainties including but not limited to those set
forth under the caption "Risk Factors" in Cogent's most recent
Annual Report on Form 10-K filed with the SEC, as well as
discussions of potential risks, uncertainties, and other important
factors in our subsequent filings with the SEC. Any
forward-looking statement speaks only as of the date on which it
was made. Neither we, nor our affiliates, advisors or
representatives, undertake any obligation to publicly update or
revise any forward-looking statement, whether as result of new
information, future events or otherwise, except as required by law.
These forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date
hereof.
Investor Contact:Christi WaarichSenior
Director, Investor
Relationschristi.waarich@cogentbio.com617-830-1653
Cogent Biosciences (NASDAQ:COGT)
Historical Stock Chart
From Apr 2024 to May 2024
Cogent Biosciences (NASDAQ:COGT)
Historical Stock Chart
From May 2023 to May 2024